Elite Diagnostics INC

Elite Diagnostics INC was paid $3.23M by Medicaid between Nov 2020 and Nov 2023, across 5 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 56% of everything it billed.

33Billing provider infoELITE DIAGNOSTICS INC
SAINT LOUIS, MO 63146

33aNPI1861987083assigned 06/29/2018

33bProvider typeClinical Medical Laboratory

28Total paid$3.23M

24GClaims33,866

24DCodes billed5

24AFirst – last monthNov 2020 – Nov 2023

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#6 of 61

Median peer was paid$85K

This provider vs. median38×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	382	$7K
2021	563	$7K
2022	332	$26K
2023	32,589	$3.19M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	56%	18,663	10,433	$1.82M
87913		42%	13,891	9,540	$1.37M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.2%	864	643	$39K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	413	332	$615.08
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	0%	35	33	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNALLAMOTHU, NAVEEN (OWNER)